Long-term Variability of Desmosine/Isodesmosine as Biomarker in Alpha-1-antritrypsin Deficiency–related COPD

Figures & data

Table 1  Clinical characteristics of the patients (n = 11) participating in the study.

Age (yrs)*	56 (29)	Gender (M/F)	9/2
Duration disease (yrs)*	10 (14)	FEV1 (L) °	1.58 (0.16)
Smoking (pack-yrs)*	14.6 (27.5)	FEV1 (% pred)°	44.2 (5)
SGRQ score*	43 (39)	Kco*	0.77 (0.91)
Perc 15 (HU) °	-960.4 (3.33)	Kco (% pred) °	50.2 (3.9)
Sat O2% °	92.5 (0.84)	FEF 50 (L) °	0.48 (0.09)

Data are expressed as * medians (range) or °mean (SE).

Table 2  Urine and plasma DES values at baseline, 6 months and 1 year

n = 11	Baseline	6 months	1 year
Urinary DES (μg/g creat) °	52.9 (4.43)	60.8 (3.3)	61 (44-93.7) *
Plasma DES (μg/L)°	27.5 (10.5 - 57.1)	35.1 (12.3-52.6)	49.1 (29.8–66.2)**
FEV1% pred^#	44.2 (5)	41.6 (5.3)	42.6 (5)
Kco% pred^#	50.2 (3.9)	46.4 (4.4)	46.3 (4.1)*

Data are expressed as ^#mean (SE) or °median (min-max).

*p < 0.05.

**p < 0.001.

Figure 1  Part a shows the desmosine/isodesmosine levels in urine collected from 11 patients at baseline and after 14 months. Patients received no alpha-1-antitrypsin augmentation treatment, but used inhaled steroids and bronchodilators. Part b shows the plasma values of the same patients.

Figure 2  Part a shows the desmosine/isodesmosine levels in urine collected between month 2 and 14 after the screening visit from a single patient. Part b shows the plasma levels of the same patient.